Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-31

Study Completion Date

2023-08-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin

NCT02970032

Deep-Venous Thrombosis Pulmonary Embolism Venous Thromboembolism

COMPLETED EARLY_PHASE1

Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients

NCT02707263

Venous Thromboembolism

WITHDRAWN NA

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

NCT03516656

Deep Vein Thrombosis Pulmonary Embolism Venous Thromboembolism

COMPLETED EARLY_PHASE1

Inpatient Monitoring of Unfractionated Heparin

NCT06329921

Blood Clot Thrombosis

ENROLLING_BY_INVITATION NA

Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)

NCT00622115

Thrombosis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Unfractionated heparin is classified as a high-alert medication in the acute care setting.3 Therapeutic anticoagulation is a high priority for healthcare teams because the impacts of inadequate anticoagulation can lead to life threatening events such as a major bleed or thrombus formation and/or death.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unfractionated Heparin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient's aged 18 years or older with a confirmed diagnosis of DVT/PE based on imaging or a confirmed diagnosis of ACS requiring heparin therapy

Exclusion Criteria

* History of bleeding in the last 30 days
* History of HIT
* Use of systemic anticoagulants for another indication
* Presence of coagulation disorder prior to admission (i.e. hemophilia, sickle cell anemia, etc.)

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No